Design Therapeutics (DSGN) Research & Development (2020 - 2026)
Design Therapeutics (DSGN) reported Research & Development of $14.4 million for Q1 2026, down 6.49% on a YoY basis from $15.4 million in Q1 2025, and up 131.53% sequentially from -$45.6 million in Q4 2025.
Design Therapeutics (DSGN) Research & Development (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Research & Development data on file, last reported at $14.4 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 6.49% year-over-year to $14.4 million; the trailing twelve-month figure through Mar 2026 stood at -$898000.0 (down 101.8% YoY), and the FY2025 full-year result was $100000.0, down 99.77% from the prior year.
- Research & Development rose to $14.4 million in Q1 2026, from -$45.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $17.1 million in Q2 2023 to a low of -$45.6 million in Q4 2025.
- A 5-year average of $9.7 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 126.04% in 2022 and tumbled 475.13% in 2025, its largest moves.
- Tracing DSGN's Research & Development over 5 years: stood at $14.3 million in 2022, then dropped by 22.75% to $11.0 million in 2023, then increased by 10.4% to $12.2 million in 2024, then plunged by 475.13% to -$45.6 million in 2025, then soared by 131.53% to $14.4 million in 2026.
- Business Quant data shows DSGN's Research & Development at $14.4 million in Q1 2026, -$45.6 million in Q4 2025, and $14.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | 14.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.38 Mn |
| Dec 31, 2025 | -45.60 Mn |
| Sep 30, 2025 | 14.59 Mn |
| Jun 30, 2025 | 15.74 Mn |
| Mar 31, 2025 | 15.38 Mn |
| Dec 31, 2024 | 12.16 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 9.80 Mn |
| Dec 31, 2023 | 11.01 Mn |
| Sep 30, 2023 | 13.26 Mn |
| Jun 30, 2023 | 17.06 Mn |
| Mar 31, 2023 | 15.73 Mn |
| Dec 31, 2022 | 14.26 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 11.30 Mn |
| Mar 31, 2022 | 8.76 Mn |
| Dec 31, 2021 | 7.34 Mn |
| Sep 30, 2021 | 8.54 Mn |
| Jun 30, 2021 | 5.03 Mn |